Tiloram tab. p / o captivity. 125mg # 10

Dosage form

Film-coated tablets from yellow to orange, round, biconvex

two layers are visible on the fracture - a film shell and an orange core, inclusions of white or orange are allowed.

Structure

1 tab.

tilorone (in the form of dihydrochloride) 125 mg

Excipients: lactose monohydrate (milk sugar) - 101 mg, microcrystalline cellulose - 45 mg, croscarmellose sodium - 9 mg, water - 5 mg, povidone K17 - 12 mg, magnesium stearate - 3 mg.

The composition of the shell: hypromellose - 5.7 mg, macrogol 4000 - 1.4 mg, titanium dioxide - 2.8 mg, tropeolin O dye - 0.1 mg.

pharmachologic effect

Low molecular weight synthetic interferon inducer that stimulates the formation of alpha, beta and gamma interferons in the body. The main producers of interferon in response to the administration of tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence intestine - liver - blood after 4-24 hours. Tilorone has an immunomodulatory and antiviral effect. In human leukocytes, it induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, including influenza viruses, other acute respiratory viral infections,hepatitis viruses and herpes viruses. The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Pharmacokinetics

After oral administration, it is rapidly absorbed from the gastrointestinal tract.

Bioavailability is 60%.

Plasma protein binding is about 80%.

Does not undergo biotransformation.

T1 / 2 - 48 hours. It is excreted unchanged in feces (70%) and urine (9%).

Does not cumulate.

Side effects

Perhaps: short-term chills, allergic reactions.

In some cases: dyspeptic symptoms.

Selling features

Available without a prescription

Special conditions

It is not recommended to use tilorone in doses exceeding recommended ones in order to avoid possible short-term depletion of immunocompetent cells.

As part of the complex therapy of neuroviral infections, tilorone is used under medical supervision.

Indications

Treatment and prevention of influenza and other acute respiratory viral infections (ARVI)

treatment of viral hepatitis A, B and C

treatment of herpes and cytomegalovirus infections

as part of the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, etc.)

as part of the complex therapy of urogenital and respiratory chlamydia

in the complex therapy of pulmonary tuberculosis.

Contraindications

hypersensitivity to tilorone and other components of the drug

period of pregnancy and lactation

children's age up to 18 years

hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption

Drug interactions

Tiloron is compatible with antibiotics, the traditional treatment for viral and bacterial diseases.

Name ENG

TILORAM

Clinical and pharmacological group

Antiviral and immunomodulatory drug.

Interferon synthesis inductor

ATX code

Other antiviral drugs

Dosage

125mg

Structure

1 tablet: tilorone (in the form of dihydrochloride) 125 mg.

Excipients: lactose monohydrate (milk sugar) - 101 mg, microcrystalline cellulose - 45 mg, croscarmellose sodium - 9 mg, water - 5 mg, povidone K17 - 12 mg, magnesium stearate - 3 mg.

The composition of the shell: hypromellose - 5.7 mg, macrogol 4000 - 1.4 mg, titanium dioxide - 2.8 mg, tropeolin O dye - 0.1 mg.

INN / Active ingredient

Tiloron

Storage conditions and periods

At a temperature not higher than 25 degrees, in its original packaging (cardboard pack).

Expiration date: 3 years

Specifications

Category

Antiviral

,

Antimicrobial agents

Scope of the medicinal product

General

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

ten

Minimum age from

18 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Ozone OOO

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

J05AX Other antiviral drugs

Dosage form

Film-coated tablets

Dosage (volume) of the substance in the preparation

125 mg

Expiration date in days

1095

The target audience

Adult

Package weight, g

twenty

Mode of application

:

For the treatment of viral hepatitis A - on the first day, 125 mg 2 times, then 125 mg every 48 hours.

For the course - 1.25 g.

For the treatment of acute hepatitis B - the first two days at 125 mg, then 125 mg after 48 hours, for the course of treatment - 2 g.

With a prolonged course of hepatitis B - 125 mg 2 times a day on the first day, then 125 mg every 48 hours.

For the course of treatment - 2.5 g.

Pharmaco-therapeutic group

:

Antiviral immunostimulating agent - inducer of interferon formation